Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.
Propranolol was granted FDA approval on 13 November 1967.
Propranolol is indicated to treat hypertension. Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.
For additional information regarding sites (California, Texas, New Jersey, Minnesota), Princeton, New Jersey, United States
Douglas Mental Health University Institute, Montréal, Quebec, Canada
Centre Hospitalier Henri Laborit, Poitiers, France
Centre Hospitalier Nord-Deux-Sèvres, Thouars, France
AP-HP Louis Mourier, Colombes, France
CHU Poitiers, Poitiers, France
CHU Rouen, Rouen, France
Hämeenlinna Central Hospital, Hämeenlinna, Kanta-Häme, Finland
Sakunta Central Hospital, Pori, Satakunta, Finland
Central Finland Central Hospital, Jyväskylä, Central Finland, Finland
Faculty Of Medicine, Minya, Egypt
Christiana Care, Newark, Delaware, United States
Departmet of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Roswell Park Cancer Institute, Buffalo, New York, United States
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.